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Mitochondrial dysfunction within the synapses of substantia
nigra neurons in Parkinson’s disease
Amy K. Reeve1, John P. Grady1,2, Eve M. Cosgrave1, Emma Bennison1, Chun Chen1, Philippa D. Hepplewhite1,3,4 and
Christopher M. Morris3,5
Mitochondrial dysfunction within the cell bodies of substantia nigra neurons is prominent in both ageing and Parkinson’s disease.
The loss of dopaminergic substantia nigra neurons in Parkinson’s disease is associated with loss of synapses within the striatum,
and this may precede neuronal loss. We investigated whether mitochondrial changes previously reported within substantia nigra
neurons were also seen within the synapses and axons of these neurons. Using high resolution quantitative fluorescence
immunohistochemistry we determined mitochondrial density within remaining dopaminergic axons and synapses, and quantified
deficiencies of mitochondrial Complex I and Complex IV in these compartments. In Parkinson’s disease mitochondrial populations
were increased within axons and the mitochondria expressed higher levels of key electron transport chain proteins compared to
controls. Furthermore we observed synapses which were devoid of mitochondrial proteins in all groups, with a significant reduction
in the number of these ‘empty’ synapses in Parkinson’s disease. This suggests that neurons may attempt to maintain mitochondrial
populations within remaining axons and synapses in Parkinson’s disease to facilitate continued neural transmission in the presence
of neurodegeneration, potentially increasing oxidative damage. This compensatory event may represent a novel target for future
restorative therapies in Parkinson’s disease.
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INTRODUCTION
Parkinson’s disease (PD) is classically associated with a loss of
dopaminergic substantia nigra (SN) neurons, however it may be
the progressive loss of their synapses and axons that leads to the
depletion in dopamine neurotransmission.1 Profound SN neuron
loss is seen in longstanding PD, although around 70% of SN
neurons need to be lost before clinical symptoms are evident,2
therefore either there is considerable redundancy within the SN
projection to the striatum or there is compensatory synaptic
sprouting as degeneration takes hold. Striatal dopamine may be
depleted by up to 80% by the time of onset of motor symptoms
and imaging has shown that changes in dopamine transporter
(DAT) expression may be helpful for monitoring of progression3
and the detection of changes in at-risk individuals.4,5
Many genes associated with familial PD also cause synaptic
dysfunction when mutated or down regulated. Perhaps the most
prominent of these is the alpha-synuclein gene, SNCA.6 A
relatively small and unstructured protein, alpha-synuclein has
been proposed to have several functions at the synapse, including
modulation of dopamine release and a regulation of ion
channels.7 Alpha-synuclein is also capable of interacting with
mitochondria and causing their dysfunction,8 indeed it has been
shown that alpha-synuclein can induce mitochondrial dysfunction
within SN neurons that precedes neuronal loss.9–11 Furthermore,
knock-down of Pink1, Parkin or DJ-1 causes synaptic dysfunction,
with reduced dopamine release and synaptic plasticity in the
striatum.12–15 Similarly, LRRK2 has been shown to interact with a
number of synaptic proteins to affect the mobilisation of synaptic
vesicles,16 and mutations in LRRK2 cause a reduction in dopamine
release into the striatum.17–19
Mitochondrial dysfunction has also been linked to SN neuronal
loss and can take the form of reduced electron transport chain
protein expression and activity,20–22 which may be caused by the
accumulation of mitochondrial DNA deletions.22,23 Pink1, Parkin
and DJ-1 encode proteins with essential mitochondrial functions
and their disruption can cause marked changes in the function
and ultrastructure of mitochondria.13,24–29 Furthermore, MPTP
treatment causes a loss of dopaminergic synapses followed by SN
cell bodies; however protection of the synaptic terminals against
oxidative stress prevents the subsequent loss of SN neurons.30,31
Electron microscopy of dopaminergic synapses within the caudate
nucleus of PD patients has revealed an increase in the synaptic
area occupied by mitochondria, however mitochondrial function
was not examined.32 More recent data has suggested that
dysfunctional mitochondria may be transported retrogradely to
the cell body for lysosomal degradation, thus ensuring that the
synapse and axon are populated by healthy mitochondria with
intact respiratory activity (reviewed in ref. 33). However it remains
unclear whether mitochondrial deficiencies are also seen within
dopaminergic axons and synapses and how they affect the
metabolically demanding process of synaptic transmission.34 Here
we investigated the contribution of synaptic changes and
mitochondrial dysfunction to the neurobiology of PD. We
measured the level of mitochondrial dysfunction and volume
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within single synapses and axons of SN neurons to ascertain
whether mitochondrial dysfunction is differentially distributed
within these neuronal compartments and the impact of this on
synaptic morphology and potential function.
RESULTS
Changes in synaptic volume in Parkinson’s disease
To ascertain whether any structural changes occurred within
synapses of substantia nigra neurons we measured the volume of
both pre-synaptic terminals and their corresponding post-synaptic
region. We employed dual immunofluorescence for the dopamine
transporter (pre synaptic terminal) and the dopamine D2 receptor
(post synaptic region) (Fig. 1) and the number of immunoreactive
objects per image was then calculated. We detected, as expected,
a significant reduction in pre-synaptic DAT positive terminals
within the putamen in PD and dementia with Lewy bodies (DLB)
cases, compared to controls and AD cases (p ≤ 0.001, n= 6 images
analysed per case, Fig. 2a). Interestingly we also detected a loss of
D2R positive, post synaptic terminals in PD and AD cases (p ≤
0.001, n= 6 images analysed per case) compared to controls and
in PD cases compared to DLB cases (p ≤ 0.01, n= 6 images
analysed per case) (Fig. 2b).
The volume of dopaminergic terminals within the striatum was
measured. This showed that there was a significant relationship
between the size of the pre and post-synaptic structures detected
in PD and DLB cases (p-values are <0.0001 and 0.0002,
respectively), based on the gradients of regression lines (Fig. 2c),
but not in the AD (p= 0.577) or control groups (p= 0.957).
Furthermore there was a trend for the pre-synaptic volume to be
increased in PD and DLB compared to controls, which reached
significance in the group analysed for synaptic volume alongside
NDUFB8 and porin (PD p= 0.0034; DLB p= 0.005).
Mitochondrial alterations in surviving dopaminergic axons within
the striatum
Mitochondria are transported to areas of the neuron which exhibit
a particularly high energy demand, for example the nodes of
Ranvier (to supply ATP for the Na+/K+ ATPase) and synapses.
Therefore we examined whether differences in the density of
mitochondria and their expression of mitochondrial complex I and
IV existed within surviving dopaminergic axons in Parkinson’s
disease (Fig. 3). Such mitochondria may either be stationary or
may be in transit, perhaps being retrogradely transported for
degradation.
When the volume of mitochondria which were immunore-
active for porin and either NDUFB8 or COXI were examined we
Fig. 1 Representative images of pre and post synaptic immunoreactivity. Synaptic terminals of dopaminergic SN neurons within the striatum
were analysed. Pre-synaptic terminals were visualised using reactivity for the dopamine transporter, DAT (green, 488 nm). Images were taken
of pre-synaptic terminals surrounding a post synaptic neuron, post synaptic regions were visualised using reactivity for the dopamine D2
receptor (red, 546 nm). Pre and post synaptic volume was measured in tissue from patients with PD (a), DLB (b), AD (c) and in age matched
controls (d). Scale bar represents 10 µm
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identified significant changes in PD. Firstly, the axons of SN
neurons in PD cases showed the highest expression of porin per
axonal volume, followed by DLB cases. This suggests that in
these situations there is an increase in mitochondrial density
per axon. Importantly, significant increases in the expression of
NDUFB8 (p= 0.0402) and COXI (p= 0.04) per mitochondrion
were also observed within these axons in PD (Fig. 4a, b). DLB
cases also showed a higher expression of these proteins within
axonal mitochondria compared to controls, but this was not
significant. Expression of these essential proteins in AD axons was
similar to the expression in controls as expected (Fig. 4a, b). In
addition, there was evidence of mitochondria that were deficient
for both NDUFB8 and COXI, and while the percentage of
mitochondria that were deficient for these key proteins was
reduced in axons in both PD and DLB cases this was not
significant (data not shown).
Mitochondrial alterations within the synapses of dopaminergic
neurons
In addition to investigating mitochondrial changes within axons
we also examined changes within dopaminergic pre-synaptic
terminals in the striatum (Supplementary figure 3). Using a similar
approach as detailed in supplementary figure 1 we detected
mitochondria located specifically within selected dopaminergic
synapses based on two parameters, those which contained
mitochondria (based upon porin immunoreactivity) and those
for which the DAT volume entirely encapsulated the mitochondria.
Once a subset of synapses had been detected the synaptic surface
was masked onto either the COXI or NDUFB8 signal and further
surfaces were created based on the expression of these proteins.
Therefore for each individual synapse we could measure synaptic
volume, mitochondrial volume and the expression of mitochon-
drial complex I or IV.
Fig. 2 Changes in synaptic volume and density are detected in PD cases. Synaptic loss has been shown to occur in Parkinson’s disease, and
has been thought to precede neuronal loss within the substantia nigra. The immunofluorescent assay used in this study and the subsequent
image analysis could detect this loss of synapses within the striatum of patients affected by PD and DLB. There was a significant reduction in
pre-synaptic DAT positive terminals in PD and DLB compared to controls and AD (***p= ≤0.001) (a). Interestingly we saw an associated loss of
post-synaptic D2R positive structures in PD and AD, but not in DLB (***p= ≤0.001; **p= ≤ 0.01) (b). Kruskal–Wallis one-way ANOVAs were
performed with Dunn’s multiple comparison testing to ascertain statistical significance. A significant increase in synaptic volume was found to
occur in PD and (c) shows the relationship between pre and post synaptic structure volume in all four patient groups. The volume of pre and
post synapses was only found to be related in PD (p= 5 × 10−6) and DLB (p= 0.0002). Error bars represent s.e.m
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When mitochondrial synaptic populations were analysed, no
significant differences were detected in either the mitochondrial
density or the expression of mitochondrial complexes I and IV
within dopaminergic synapses of the striatum. Interestingly we
detected empty dopaminergic pre-synaptic terminals that
appeared devoid of mitochondria in all groups (Fig. 5a–d). When
the percentage of empty synapses was calculated it was found
that there was a significant reduction in the proportion of these
empty synapses in PD and DLB cases compared to controls and
AD cases (p ≤ 0.001) (Fig. 5e). A significant relationship (p= 0.04)
was found between the level of Complex I deficiency within the
SN and the number of empty synapses in PD, such that the greater
the deficiency for complex I within the cell body the more empty
synapses were detected within the striatum (Supplementary
figure 4). The number of synapses which were complex I or IV
deficient did not differ between the four groups. Furthermore,
there was no correlation found between the percentage of
synapses which were devoid of mitochondria and overall pre-
synaptic terminal number which may have suggested a contribu-
tion to the degeneration of these synapses.
Are alterations in the axonal and synaptic mitochondrial
populations correlated with respiratory deficiency in the soma?
Although in human tissue it is not possible to compare cell body
changes to synaptic/axonal changes within the same neuron, a
measure of respiratory chain deficiency was made within the
soma of SN neurons for most of the cases included in this study
(with the exception of control 7, AD9, DLB8 and PD3). Intensity
measurements were made for immunoreactivity for NDUFB8, COXI
and porin within TH positive cell bodies within the SN. A reduction
in expression of either of these proteins was defined as an
intensity value that had a z score of less than −1, normal neurons
had a score of between −1 and 1, while an increase was defined
as having a score over 1. These parameters were set based on the
control data.
There was an increase in the percentage of cell bodies showing
reduced expression of both complex I and complex IV in PD cases
compared to other groups, and in DLB cases there was an increase
in complex IV deficient neurons, however neither of these changes
was significant due to the variability between cases (Fig. 5f, g). In
addition to measuring deficiency within the neurons of the SN,
mitochondrial density was also quantified. Using the signal
intensity for porin immunoreactivity we categorised each neuron
based on the z score for porin. We again found that there was no
significant difference between the mitochondrial mass in cell
bodies between any of our patient groups (data not shown).
Additionally, we found no correlation between the level of
mitochondrial deficiency within the SN and the changes detected
in the axonal mitochondrial population or that it drove the
mitochondrial population size within the synapse.
Fig. 3 Representative images of immunofluorescence to investigate axonal populations of mitochondria. Triple immunofluorescence for
dopaminergic axons (tyrosine hydroxylase), mitochondrial mass (porin) and either mitochondrial complex I or IV was performed on striatal
sections from cases with PD (a), DLB (b), AD (c) and Controls (d). A nuclear counterstain was used, DAPI. The mitochondria within individual
axons could then be analysed using IMARIS analysis software. Scale bar represents 10 µm
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To determine if any changes in mitochondrial function in cell
soma were associated with changes in lysosomal function or
mitophagy, LAMP2A staining was used to determine lysosomal
mass in PD. When analysing all neurones within the SN, no overall
change in lysosomal mass was seen between PD and control cases
(data not shown). When analysing only cells showing mitochon-
drial deficiency, LAMP2A levels in individual neurones in PD and
controls did however correlate with mitochondrial deficiency, with
neurones showing reduced levels of complex I expression
showing reduced LAMP2A levels (p < 0.001; Supplementary Figure
5). PD neurons in general showed higher levels of LAMP2A than
control neurons showing equivalent levels of complex I deficiency
(p= 0.0081; Supplementary figure 5).
The relationship between synaptic changes and cell body loss
within the substantia nigra
To understand whether the synaptic changes detected were
related to the degeneration of SN neurons we quantified the
number of cell bodies within the SN and investigated the
relationship between synaptic alterations and the amount of cell
loss. As expected a significant reduction in cell number was seen
in PD (p= ≤ 0.01) and DLB cases (p= < 0.05), compared to both
control and AD cases (Supplementary figure 6a). Furthermore, we
investigated whether any correlation existed between SN cell
body loss and either the prevalence of empty dopaminergic
synapses (Supplementary figure 6b) within the striatum or with
the pre-synaptic volume (Supplementary figure 6c). No significant
relationships were found in either instance. In general, in PD and
DLB there was more cell loss seen in cases with fewer empty
synapses and this relationship fitted the data most strongly for the
PD cases, while a general trend was seen for the pre-synaptic
volume to be increased in cases with severe cell loss.
DISCUSSION
Mitochondrial distribution within neurons is essential to facilitate
the provision of ATP to regions of the cell that are particularly
energy demanding such as the synapses. At synapses mitochon-
dria provide ATP and are also crucial for Ca2+ buffering. Previous
studies have shown that mitochondrial populations within axons
and synapses can be altered to compensate for pathological
changes, for example, during demyelination in multiple sclerosis35
or may be disturbed by pathological changes such as amyloid-
β.36,37 While in mice with a knockout of a key complex I subunit
(NDUFS4) neurodegeneration has also been found to be driven by
respiratory deficiency within pre-synaptic terminals, including
within the brainstem.38 Furthermore disruption of mitochondrial
Fig. 4 Mitochondrial changes within surviving dopaminergic axons. Mitochondrial density per axon, based upon porin immunoreactivity was
highest in cases with PD, when measured in conjunction within both COXI (a, *p= 0.0261) and NDUFB8 (b, *p= 0.0397). However there was
also significant increase in the expression of both COXI (c, *p= 0.0359) and NDUFB8 (d, *p= 0.0112) in the axons of patients affected by PD. A
significant increase in NDUFB8 expression was also detected in dopaminergic axons in DLB (*p= 0.01350)
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fission through the knockout of DRP1 causes dopaminergic
neuronal degeneration associated with a severe reduction in
mitochondrial mass within the axons of SN neurons.39 Therefore
given the evidence to suggest that neurodegeneration of
dopaminergic synapses may occur prior to the loss of cell bodies
within the SN in PD, we wanted to establish if there were any
changes in the mitochondrial populations within the axons and
synapses of SN neurons that indicated degeneration or compen-
satory events. A disruption of these populations or an increase in
mitochondrial deficiency within them may give further clues to
the contribution of mitochondrial dysfunction to the pathogenesis
of PD.
Synaptic and axonal alterations in Parkinson’s disease
We found that there was no difference in either the volume of
individual mitochondria or their expression of key electron
transport chain proteins, within dopaminergic synapses in PD
compared to age matched controls and Alzheimer’s disease cases.
While we confirmed a loss of dopaminergic terminals in PD and
DLB, the remaining pre-synaptic terminals were enlarged in PD
compared to those in controls. This suggests that in PD and DLB
pre-synaptic terminals expand with consequent increases of
mitochondrial numbers to compensate for the loss of neighbour-
ing synapses and that in the presence of neurodegeneration the
mitochondrial populations are maintained within single synapses.
The overall effect of this would be a compensatory attempt to
maintain synaptic transmission in remaining neurons and to
support continued communication with striatal neurons.
We also examined the mitochondrial populations within the
axons of SN neurons. Our analysis revealed that total mitochon-
drial volume was increased in axons and that the expression of
mitochondrial complex I and IV subunits was significantly
increased per mitochondrion in PD compared to controls and
Alzheimer’s disease cases. An increase in electron transport chain
proteins would suggest that these mitochondria are producing
more ATP to support the maintenance of electrical excitability in
Fig. 5 Analysis of empty synapses and respiratory deficiencies within the soma of SN neurons. Using triple immunofluorescence synapses
containing no mitochondrial signal were detected. Within a population synapses which contained mitochondria (white, open arrowhead)
were found alongside those with no mitochondria (yellow, closed arrowhead) (a). Surfaces for both types of synapse can be created (b) and
when these surfaces are mapped onto the signal for porin it becomes clear that these empty synapses are deficient for porin (c) compared to
their counterparts (d). e The percentage of synapses that were devoid of mitochondria was then calculated in each group of patients, there
was a significant reduction in the number of these synapses in PD and DLB (***p= ≤0.001). Using quadruple immunofluorescence for TH,
COXI, NDUFB8 and porin, the percentage of neuronal cell bodies within the SN that were deficient for NDUFB8 (f) or COXI (g) could be
calculated. The number of cell bodies which were deficient for these proteins was found to be increased in PD and DLB, but not significantly.
Scale bar represents 3 µm. Kruskal–Wallis one-way ANOVAs were performed with Dunn’s multiple comparison testing to ascertain statistical
significance. Error bars represent s.e.m
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these cells even in the presence of neurodegeneration. One
possibility however, is that the increase in mitochondrial volume
within axons is due to a defect in degradation, potentially due to
defective mitophagy.40,41 Elevated mitochondrial volumes may be
due to decreased mitophagy leading to a build-up of damaged
mitochondria within axons and synapses. However, the mitochon-
dria within the axons and synapses do not appear to be grossly
altered, showing normal expression of respiratory chain complex
subunits similar to control populations and, importantly, similar
levels of complex deficiency. This suggests that, at least within
axons and synapses, the increased mitochondrial volume is due to
increased production rather than a defect in degradation. Within
cell bodies we also do not observe increased mitochondrial
density suggesting a build-up, rather than an increase in defective
mitochondria showing respiratory deficiency. This may indicate
that potentially defective mitochondria are not being removed by
mitophagy. To explore this we used LAMP2A as a lysosomal mass
marker which showed no change in overall lysosome mass
between PD and controls. Mitochondrial deficiency did however
correlate with reduced LAMP2A expression. This agrees to an
extent with evidence that indicates lysosomal depletion occurs in
PD SN neurons which may be due to ROS derived from defective
mitochondria,42 however in rodent models of PD increased
mitophagy is a feature.43 The reduced energy supply due to
mitochondrial deficiency may lead to reduced lysosome produc-
tion in deficient neurones suggesting lysosomal deficiency in
single neurons is due to energy deficiency. The current findings in
cell bodies of respiratory deficient SN neurones may indicate
reduced mitophagy, although further work will be needed to
define this.
The axonal mitochondrial population is a dynamic one.
Mitochondria are transported both anterogradely and retro-
gradely along axons to be either delivered to sites where they
are required or to be degraded. A dysregulation or failure of
mitochondria to be correctly transported, especially in the
presence of respiratory dysfunction, could lead to detrimental
effects which may further contribute to neurodegeneration. When
we studied the mitochondrial population within the cell bodies of
these neurons we found that despite an increase in respiratory
deficiency in PD and DLB there was no change in the
mitochondrial density, again suggesting that in the face of
mitochondrial dysfunction the neuron maintains the mitochon-
drial population as a compensatory response to maintain neuronal
function. A recent study examining age related degeneration of
retinal ganglion cells has shown that prior to neurodegeneration
mitochondrial transport declines and areas appear within axons
that are devoid of mitochondria.44,45 Furthermore, the ablation of
Milton, an important mitochondrial transport protein, in Droso-
phila photoreceptors leads to alterations of synaptic transmission
and an increase in synapses which are devoid of mitochondria,
which drives the degeneration of photoreceptors in these flies.46
The increased mitochondrial population of surviving axons
observed in this study may be due to the presence of increased
numbers of damaged synaptic mitochondria being transported
back to the cell body for degradation. However we also detected
an increase in electron transport chain protein subunits that have
previously been shown to correlate with mitochondrial function.
Alternatively, given the finding of enlarged synapses with
maintained mitochondrial populations in PD, the increase in
axonal mitochondria may represent part of a compensatory
process where newly derived mitochondria en-route to dopami-
nergic synapses to maintain synaptic function. Methods to detect
mitochondria targeted for degradation will be required to resolve
this issue.
We also found that we could detect a population of synapses
which appeared devoid of mitochondrial proteins in the normal
and pathological brain, the number of which was reduced in DLB
and PD compared to controls. An observation that has previously
been detected in cultured neurons and hippocampal slices.47–49
The purpose and functionality of these empty synapses is unclear
as although synaptic neurotransmission has a high mitochondrial
and glycolytic requirement for ATP,34 it is unlikely that these
empty synapses would be functional for long periods of time. It is
possible that under normal circumstances these empty synapses
might represent a reserve pool which can be called in to use in
periods of high functional demand. Given our findings of enlarged
synapses, increased axonal mitochondria, and proportional
reductions of empty synapses in PD and DLB, this may again be
a compensatory attempt to maintain synaptic dopaminergic
transmission in the face of neurodegeneration and dopamine
deficiency. Previous research has shown that 6-OHDA lesions
cause axonal degeneration with an associated loss of synaptic
terminals, however following degeneration there is evidence of
compensatory axonal sprouting followed by recovery of striatal
synapses.50 Indeed, our preliminary studies in the 6-OHDA rat
model indicate similar changes in synaptic mitochondria to those
seen in PD and DLB tissue (Reeve et al., unpublished). If a specific
amount of dopamine release from SN synapses is needed to
modulate the firing of striatal interneurons, it could be argued that
sufficient dopamine must be released under normal circum-
stances from either a small number of SN neurons, or that only
low levels of dopamine are required to effect a change in striatal
interneuron firing. Compensation over the suggested 5–10 year
prodromal period2 might lead to either increases in the number of
synapses to effect the same striatal response or to increased
synaptic activity in the remaining synapses. Factors which lead to
synaptic dysfunction and axonal targeting might therefore alter
the response of SN neurons to progressive degeneration in PD.
What is of major interest is how this process of reducing the
number of empty synapses is regulated, as the identification of
the systems which govern this process may be targets for
therapeutic intervention to support increased levels of neuro-
transmission in PD.
Given that this a post mortem study, we can only examine the
changes that have occurred by the end stage of the disease
process, thus it is possible that the neurons that have been lost are
those with mitochondrial dysfunction within their synapses.
However, the identification of similar results in DLB cases with
intermediate levels of SN loss (and a milder parkinsonian
phenotype51,52), suggest that the findings are of an early
compensatory change. The data presented here supports the
hypothesis that remaining SN neurons within the nigrostriatal
pathway attempt to compensate for the loss of neighbouring cells
by increasing their synaptic volumes and by increasing mitochon-
drial populations to support continued neural transmission. The
reduction in the prevalence of empty synapses in PD and DLB
could suggest their recruitment in PD, as the data from Stowers
et al. (2002) might suggest,46 which would support the increase in
Milton controlled trafficking of mitochondria. The toxin MPTP
causes mitochondrial dysfunction through the inhibition of
mitochondrial complex I, but in model systems it has also been
shown to inhibit the transport of mitochondria within axons
leading to synaptic loss.53 An ability to transport functional
mitochondria through the Milton/Miro pathway appears crucial for
neuronal and synaptic survival. Finally, many neurons within the
SN accumulate mitochondrial dysfunction with advancing age.22
Therefore one hypothesis would be that to maintain neuronal
function, and since ATP is required for axonal transport, functional
mitochondria should be mobilised along axons and to synapses. In
either scenario the axons and synapses studied are those which
have survived longest and the argument could be made for these
changes in synapses and mitochondria to be protective. If this is a
general compensatory neuronal response mechanism to increase
synaptic function following degeneration is however, unclear.
Different neuronal populations are affected in diverse neurode-
generative disorders and it would be of interest to determine if
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specific neurones in other brain regions affected by neurodegen-
eration respond in the same way.
CONCLUSIONS
Despite significant neuronal and synaptic loss in PD, dopaminergic
neurons maintain healthy mitochondrial populations within their
synapses and axons, with mitochondria showing a normal
respiratory chain complement. This along with an increase in
the volume of pre-synaptic terminals may represent a compensa-
tory mechanism. Furthermore there is a reduction in the
percentage of synapses that are devoid of mitochondria in PD
and DLB, suggesting that this is a compensatory mechanism to
prevent synaptic dysfunction and loss.
METHODS
Tissue
All human tissue for this study was obtained from the Newcastle Brain
Tissue Resource. Consent for the use of all tissue had been given by the
donors or next of kin with permission of the National Health Service Local
Research Ethics Committee and use conformed to the UK MRC Guidelines
on the use of tissue in medical research. Serial coronal transverse formalin-
fixed, paraffin-embedded sections of putamen and transverse upper
midbrain were cut at a thickness of 5 µm from 10 PD cases, 10 DLB cases
and 11 Alzheimer’s disease cases (included as a disease control) (Table 1).
All cases were pathologically and clinically confirmed. These cases were
compared to 11 age matched controls with only age-associated
pathological changes. Details of the cases used for this study can be
found in supplementary table 1.
Immunohistochemistry
Double immunofluorescence was used to measure the volume of
dopaminergic synapses within the striatum. To do this we utilised
antibodies for the dopamine transporter (DAT) to label pre-synaptic
terminals and the dopamine D2 receptor (D2R) to label post synaptic
regions. We then utilised triple immunofluorescence to allow the
quantification of mitochondrial mass (porin) and mitochondrial respiratory
chain proteins (complex I 20 kDa (NDUFB8, C120) or cytochrome c oxidase
subunit I (COXI)) within either single axons (with tyrosine hydroxylase; TH)
or single pre-synaptic terminals (DAT). A final combination of TH, COXI,
NDUFB8 and porin, or NDUFB8 and LAMP2A to define lysosomal mass was
applied to upper midbrain sections to allow a measure of mitochondrial
deficiency to be calculated in the cell bodies of dopaminergic neurons
within the SN.
The protocol used was modified from that previously reported.54 Briefly,
sections were deparaffinised and rehydrated through an ethanol series.
Antigen retrieval was performed in 1 mM EDTA (pH 8.0, Affymetrix Inc) at
high temperature and with pressure. Non-specific binding was blocked
with a 30minute incubation in 1% normal goat serum (Sigma) diluted in
phosphate buffered saline (PBS), which was also used to dilute primary and
secondary antibodies. Primary antibodies were applied and incubated for
90min at room temperature. Following appropriate washes in PBS,
fluorescently conjugated secondary antibodies were applied and incu-
bated for 60min at room temperature (see supplementary table 2 for
details). Following PBS washes 2 mM Hoechst (ThermoFisher) was applied
and incubated for 30min to give a nuclear counterstain. Again the sections
were washed in PBS before a final 10 min incubation in Sudan black (in
70% EtOH) to quench autofluorescence. After application of Sudan black
(BDH) sections were washed rapidly in PBS with 0.1% Tween to remove
excess solution and then in PBS. Sections were then mounted using
Prolong Gold Antifade (ThermoFisher) and stored at −20 ˚C before
imaging.
Cresyl fast violet (CVF) stain and cell counts
CFV staining was performed to allow dopaminergic neuronal counts to be
performed. Three 20 µm thick sections of upper midbrain were cut, stained
using CFV (Sigma) and used to count the cell bodies of the dopaminergic
neurons.55 Two-dimensional cell counts were performed as described
previously.55,56 The SN was outlined at a low magnification and a meander
scan through this region performed. Neurons were counted that contained
neuromelanin and a clearly defined nucleus. The cell count for each
section was then calculated as a percentage of the mean control cell count
for all control sections/cases.
Image analysis and quantification
Sections were imaged using a Nikon A1R Confocal microscope and NiS
elements software. Z-stack images were taken using a x63 oil immersion
objective and the Z-stack controlled using a Piezo drive. The settings for
laser power, gain and offset were set on ‘no primary’ and single stained
controls (whereby one primary was applied followed by the cocktail of
secondary antibodies), for each staining run. These settings were then
used to image all cases. Image capture and analysis was done blind to
disease status. Based on power calculations, six Z stack images were
captured per case ensuring the capture of a number of synapses or at least
two axons per image. Images were then analysed using IMARIS software
(Bitplane, Oxford Instruments).
Synapse morphological analysis
To analyse synaptic volume based on DAT and D2R immunoreactivity, Z
stacks were deconvolved, imported into IMARIS and resized according to
their original dimensions (Supplementary figure 1a). Surfaces were created
for DAT positive pre-synaptic terminals (green) and D2R positive post-
synaptic terminals (Red) (Supplementary figure 1b). Once these surfaces
had been created (Supplementary figure 1c), synapses were identified as
locations where the green and red surfaces touched (Supplementary figure
1d). These synapses were then analysed for total synaptic volume as well
as pre and post-synaptic terminal volume. The number of pre and post-
synaptic terminals per unit area was also recorded.
Axonal analysis
Each Z stack was deconvolved, imported into IMARIS and resized
depending on its original dimensions (Supplementary figure 2a). The
axonal tyrosine hydroxylase staining was selected (the 647 nm channel,
purple) and a surface was created based on this stain (Supplementary
figure 2b & c). The length and volume of each axon was recorded in order
to allow expression of measured metrics per unit axonal length or volume.
This axonal mask was applied onto the porin channel (546 nm, red), which
allowed the mitochondria located within axons to be selected (Supple-
mentary figure 2d). Once these mitochondria had been selected a second
surface was created for the porin positive mitochondria, based on no
primary controls the staining intensity boundaries were set between 500
and 4095 (the saturation intensity), while the smoothness was set at 0.1
and the background subtraction at 0.5. The process was then repeated for
either NDUFB8 or COXI (488 nm channel, green), with the intensity
boundaries between 400 and 4095 (Supplementary figure 2e). Each axon
was selected in turn and the volume and number of mitochondria positive
for porin and NDUFB8 or COXI was analysed (Supplementary figure 2f).
Table 1. Mean age and PM delay for cases used
Disease Mean age (years) Age range (years) Mean PM delay (hours) Sex
PD 80.8 70–92 46.3 (15–88) 3 female/7 male
DLB 77.5 71–88 39.6 (8–68) 3 female/7 male
AD 83.4 75–88 54.9 (29–82) 5 female/6 male
Dementia with Lewy bodies 80.8 69–89 31.8 (8–64) 6 female/ 5 male
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Synaptic mitochondrial analysis
Each Z stack was deconvolved, imported into IMARIS and resized
depending on its original dimensions. The synaptic terminal staining
(DAT, 488 nm, green) was selected and a surface was created. The
smoothness was set at 0.1 and the background subtraction at 0.75, while
the limit of fluorescence intensity was set at 4095. The volume of each
synaptic terminal was recorded and used to express measured metrics per
unit synaptic volume. This mask was applied onto the porin channel
(647 nm, purple), which allowed the mitochondria located within synapses
to be selected. Based on no primary controls the staining intensity
boundaries were set between 500 and 4095, while the smoothness was set
at 0.1 and the background subtraction at 0.5. To avoid biased selection a
subset of synapses were chosen for which the porin immunoreactivity was
encapsulated completely within the DAT surface. Once these synapses had
been selected, they were masked onto the NDUFB8 or COXI channel
(546 nm channel, red) and a third surface was created for the respiratory
chain proteins, with the intensity boundaries between 400 and 4095. Each
synapse was then analysed in turn and the volume of Porin and NDUFB8 or
COXI positive mitochondria was recorded.
Cell body analysis
To allow a measurement of mitochondrial deficiency within the cell bodies
of SN neurons we performed quadruple immunofluorescence as described
above. Twenty five, single plane images were taken per case at x40
magnification. Neurons were identified by the presence of neuromelanin, a
defined nucleus and a positive signal for TH. The area of each cell body
was then defined and the signal intensity per unit area was measured.
Measurements from no primary controls were also taken and these values
subtracted from the intensities gathered from positively stained neurons.
Similarly, we measured complex I deficiency in neurones using NDUFB8
and lysosomal mass using LAMP2A and the intensity per unit area
determined.
Statistical analysis
For all data analyses, Box Cox regression was used when appropriate to
identify optimal data transformation to achieve normality. Additional linear
regression, t tests or one-way ANOVAs were used where appropriate for
statistical testing. For the measurement of deficiency within the cell body,
the intensities were log transformed and normalised to porin, Z scores
were then calculated.
Data availability statement
All data generated or analysed during this study are included in this
published article (and its supplementary information files).
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